Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tovinontrine - Cardurion Pharmaceuticals

Next Previous
Drug Profile

Tovinontrine - Cardurion Pharmaceuticals

Alternative Names: 68722; AF68722; CK1598; CRD-750; IMR-687

Latest Information Update: 13 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Developer Cardurion Pharmaceuticals; Enliven Therapeutics
  • Class Antianaemics; Heart failure therapies; Imidazoles; Pyrans; Pyrazines; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Beta-thalassaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure
  • Discontinued Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

  • 06 Aug 2025 Cardurion Pharmaceuticals completes enrolment in the phase II Cycle-1-REF trial for Chronic heart failure in USA, Australia, Belgium, Bulgaria, Canada, Czech Republic, Georgia, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, New Zealand, Poland, Slovakia, Spain, Taiwan, United Kingdom (PO) (NCT06215911)
  • 06 Aug 2025 Cardurion Pharmaceuticals completes the enrolment in the phase II Cycle-2-PEF trial for Chronic heart failure in USA, Australia, Belgium, Bulgaria, Canada, Czech Republic, Germany, Hungary, Italy, the Netherlands, New Zealand, Poland, Spain, Taiwan, United Kingdom (PO) (NCT06215586)
  • 31 Mar 2024 Phase-II clinical trials in Chronic heart failure in USA (PO) (NCT06215586)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top